Onconetix Lands $30.25M Premium PIPE and $750M Equity Line
ONCO sits 18% above its 52-week low of $0.711.
Summary
Onconetix raised $30.25M in a PIPE priced above market and secured a $750M equity line, providing essential capital but with terms that could heavily dilute existing shareholders if the stock price weakens.
Key Events · Financing and Capital Events · ONCO
-
$30.25M PIPE at Premium
The company sold 37,812 shares of Series F convertible preferred stock at a stated value of $1,000 each, convertible at $0.9767 per share — a premium to the current $0.84 price. Gross proceeds of $30.25M provide immediate liquidity.
-
$750M Equity Line Established
A Common Stock Purchase Agreement (ELOC) allows the company to sell up to $750M of common stock over time, subject to a 19.99% exchange cap. The ELOC investor received a $30M commitment fee, which was applied toward the PIPE.
-
Highly Dilutive Conversion Terms
The Series F preferred stock includes a 15% default dividend, alternate conversion rights at 90-95% of the lowest VWAP, and a floor price of $0.19534. If triggered, these features could massively increase the share count.
-
Survival Financing for Distressed Company
This financing follows a going-concern warning, material weaknesses, and a 1-for-10 reverse split in May 2026. The capital extends the runway but does not resolve underlying operational challenges.
Analysis · ONCO · Life Sciences
On July 28, 2026, Onconetix closed two financing agreements that could reshape its capital structure. The first is a $30.25 million PIPE for Series F convertible preferred stock, priced at a conversion rate of $0.9767 per share — a premium to the current $0.84 stock price, signaling institutional confidence despite the company's distressed history. The second is a $750 million committed equity facility (ELOC) that gives the company the right, but not the obligation, to sell shares over time. Use of the ELOC is capped at 19.99% of outstanding shares unless stockholders approve a higher limit. The PIPE investor received a $30 million commitment fee, which was applied toward the PIPE purchase. The Series F stock carries a 15% default dividend, alternate conversion rights at a discount to market, and a floor price of $0.19534 — terms that could lead to substantial dilution if triggered. Against a backdrop of a going-concern warning, material weaknesses, and a recent reverse split, this financing package provides critical runway but introduces complex, potentially highly dilutive instruments.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 44% of the 562 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONCO was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $0.71 to $229.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.